Posted at 30 Jul, 14:52h in Press Release by adialpharma 0 Comments 0 Likes Share Adial Pharmaceuticals Schedules Business and Clinical Update Conference Call
Posted at 22 Jul, 14:15h in Press Release, Uncategorized by adialpharma 0 Comments 0 Likes Share Adial Pharmaceuticals Receives European Medicines Agency (EMA) Agreement on the Pediatric Investigation Plan (PIP) for AD04 in Alcohol Use Disorder
Posted at 06 Jul, 12:24h in Press Release by adialpharma 0 Comments 0 Likes Share Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Sweden and Estonia
Posted at 25 Jun, 14:48h in Press Release by adialpharma 0 Comments 0 Likes Share Adial Pharmaceuticals Announces Commencement of Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland
Posted at 17 Jun, 16:17h in Press Release by adialpharma 0 Comments 0 Likes Share Adial Pharmaceuticals Announces Commencement of the Landmark ONWARD(TM) Pivotal Phase 3 Clinical Trial in Latvia
Posted at 15 Jun, 16:17h in Press Release by adialpharma 0 Comments 0 Likes Share Adial Pharmaceuticals Closes Previously Announced $5.2 Million Registered Direct Offering
Posted at 15 Jun, 16:17h in Press Release by adialpharma 0 Comments 0 Likes Share Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD™ Pivotal Phase 3 Trial in Poland
Posted at 06 Feb, 20:01h in Press Release, Uncategorized by adialpharma 0 Comments 0 Likes Share Adial Pharmaceuticals Commences Phase 3 Trial of AD04 for Alcohol Use Disorder
Posted at 09 Jan, 14:27h in Press Release by adialpharma 0 Comments 0 Likes Share Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Finland
Posted at 17 Oct, 14:34h in Press Release by adialpharma 0 Comments 0 Likes Share ADIAL PHARMACEUTICALS RECEIVES NOTICE OF ALLOWANCE FROM US PATENT AND TRADEMARK OFFICE FOR PATENT FOR THE TREATMENT OF ALCOHOL USE DISORDER IN PATIENTS IDENTIFIED USING A MOLECULAR GENETIC BIOMARKER
